AbbVie’s 2.7% dividend yield exceeds the S&P 500’s 1% and pharma sector’s 1.5%, supported by strong cash flow despite a high payout ratio.
AbbVie’s dividend yield stands at 2.7%, significantly higher than the S&P 500’s 1% and the pharmaceutical sector’s 1.5% average. The company has increased its dividend annually since its 2013 spin-off from Abbott, maintaining its Dividend King status through inherited legacy and consistent growth.
While AbbVie’s earnings-based payout ratio appears elevated at 330%, its cash dividend payout ratio is a more sustainable 60%. The company’s investment-grade balance sheet and recurring cash flows from drug sales underpin dividend reliability. Analysts note that cash flow metrics provide a clearer view of dividend sustainability than earnings alone.
AbbVie’s drug portfolio remains a key driver of financial strength, supporting its ability to maintain and grow dividends. The stock’s yield and financial stability continue to attract income-focused investors despite sector volatility.